Press releaseGlobe Newswire
Oric Pharmaceuticals
ORIC · NASDAQ
$13.78+$1.06 (+8.33%)TodayMarket closed ·
Prev close $12.72
Latest news
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- Press releaseGlobe Newswire
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
- Press releaseGlobe Newswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- Press releaseGlobe Newswire
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- Press releaseBusiness Wire
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- News
Market-Moving News for April 1st
- NewsAvi Kapoor
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsAvi Kapoor
Methanex Posts Downbeat Q4 Results, Joins Gap, Nutex Health, Owlet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Press releasePRNewswire
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
- NewsAvi Kapoor
This Helmerich and Payne Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Friday
- NewsAvi Kapoor
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- NewsAvi Kapoor
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
- NewsVandana Singh
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Watching Oric Pharmaceuticals; Shares See Volume As Traders Circulate Unconfirmed Analyst Comments Suggesting They Have Discovered An Accidental Release Of A Snippet On The ASCO-GU Daily News Website Highlighting Mevrometostat In Prostate Cancer With Data
- Press releasePRNewswire
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
- Press releaseBusiness Wire
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it's Board of Directors
- Press releasePRNewswire
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.